Stock data
Protalix BioTherapeutics, Inc. (DE) (PLX)
Protalix BioTherapeutics, Inc. (DE) (PLX) reported revenue of US$52.74M and net income of -US$6.60M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$52.74M | — | -US$5.50M | -US$6.60M | — |
| 2024 | US$53.40M | — | US$3.92M | US$2.93M | — |
| 2023 | US$65.49M | — | US$10.46M | US$8.31M | — |
| 2022 | US$47.64M | — | -US$13.01M | -US$14.93M | — |
| 2021 | US$38.35M | — | -US$20.46M | -US$27.58M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$19.90M | US$3.78M | — |
| 2026-03-31 | US$33.75M | US$18.32M | — |
| 2025-12-31 | US$9.12M | -US$5.50M | — |
| 2025-09-30 | US$17.85M | US$2.35M | — |
| 2025-06-30 | US$15.66M | US$0.16M | — |
| 2025-03-31 | US$10.11M | -US$3.62M | — |
| 2024-12-31 | US$18.22M | US$6.49M | — |
| 2024-09-30 | US$17.96M | US$3.24M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.